US Inks Another Deal with Pfizer and BioNTech to Vaccinate Every American by 2021

US pharma behemoth Pfizer Inc (NYSE:PFE) and German company BioNTech SE (Nasdaq: BNTX) have signed another deal with the US government to supply an additional COVID-19 vaccine dose. With the new agreement, the Companies will supply additional 100 million doses of BNT162b2 from its US based manufacturing facilities.

The two partners anticipate providing total 200 million vaccine doses to Operation Warp Speed (OWS) by the end of July 2021.

Moreover, in line with the previous agreement that was announced in July 2020, the government shall pay almost US$1.95 billion for the new deal of 100 million BNT162b2 doses.

This new purchase by the US government can offer Americans even more confidence that the nation will have enough COVID-19 vaccine supply to vaccinate every person in the US who wants the vaccine by June 2021.

Under the terms of this new agreement, the two vaccine developers will provide minimum 70 million of the additional doses by the end of June 2021 and the residual 30 million doses of the vaccine are targeted to be supplied by the end of July 2021.

Besides, the US government also has the option to acquire additional 400 million doses of the COVID-19 vaccine- BNT162b2.


Disclaimer
The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

Ad

GET A FREE STOCK REPORT


Top Penny Picks under 20 Cents to Fit Your Pocket! Get Exclusive Report on Penny Stocks For FREE Now.


   

Kalkine

Rated 4.3/5 based on 904 Reviews at Google My Business
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK